Restore Medical gets FDA breakthrough device status for ContraBand device in heart failure
Restore Medical, a leader in interventional cardiology innovations, has achieved a significant milestone with the U.S. Food and Drug Administration's (FDA) Breakthrough Device Designation for ... Read More
Cardurion Pharmaceuticals reveals breakthrough results in heart failure treatment with PDE9 inhibitor
In a significant development for cardiovascular disease treatment, Cardurion Pharmaceuticals, Inc., a clinical-stage biotechnology company, has presented positive results from its Phase 2 proof-of-concept clinical ... Read More
China’s NMPA expands AstraZeneca’s Forxiga use as heart failure treatment
China's National Medical Products Administration (NMPA) has approved AstraZeneca's Forxiga (dapagliflozin) for diminishing the risk of cardiovascular fatalities and hospitalizations in adults diagnosed with symptomatic ... Read More
Hyloris Pharmaceuticals buys global rights to CRD-102 from Baker Institute
Hyloris Pharmaceuticals has acquired the global rights from Australia-based Baker Heart and Diabetes Institute (Baker Institute) to CRD-102, a clinical-stage, extended-release Milrinone capsule. CRD-102 is ... Read More
AstraZeneca’s Forxiga wins approval in China for heart failure treatment
AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular ... Read More
Novartis reveals positive results from Entresto Phase 4 TRANSITION study for heart failure patients
Swiss pharmaceutical giant Novartis has announced encouraging results from the TRANSITION phase 4 clinical trial, affirming that Entresto (sacubitril/valsartan) can be safely initiated early in ... Read More